Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

104.63 -1.03 (-0.97%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,624,068
Open 104.60
Bid (Size) 104.78 (300)
Ask (Size) 104.89 (300)
Prev. Close 105.66
Today's Range 104.20 - 105.75
52wk Range 73.31 - 105.84
Shares Outstanding 2,531,374,696
Dividend Yield 3.10%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merck to Participate in the Citi 2025 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
From Merck Sharp & Dohme
Via Business Wire

Performance

YTD
+5.5%
+5.5%
1 Month
+18.9%
+18.9%
3 Month
+24.5%
+24.5%
6 Month
+37.4%
+37.4%
1 Year
+3.0%
+3.0%

More News

Read More
News headline image
Dow Jones Navigates Volatility Amidst AI Bubble Fears and Shifting Fed Expectations
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study ↗
Via Stocktwits
News headline image
Stocks making big moves yesterday: Meta, Tenet Healthcare, Wynn Resorts, Elevance Health, and Merck
Via StockStory
Topics Artificial Intelligence
News headline image
Why Merck (MRK) Stock Is Trading Up Today
Via StockStory
Topics Artificial Intelligence Economy
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
From BioMedWire
Via GlobeNewswire
News headline image
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
From Merck & Co., Inc.
Via Business Wire
News headline image
Q3 Earnings Outperformers: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
From Merck & Co., Inc.
Via Business Wire
News headline image
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy World Trade
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know. ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Via The Motley Fool
News headline image
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗
Via MarketBeat
News headline image
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗
Via Benzinga
News headline image
2 Healthcare Stocks Worth Your Attention and 1 We Ignore
Via StockStory
Topics Stocks
News headline image
Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗
Via MarketBeat
News headline image
Healthcare Rotation Underway: 3 Stocks Leading the Charge ↗
Via MarketBeat
News headline image
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
From Merck & Co., Inc.
Via Business Wire
News headline image
Healthcare Sector Navigates Volatile Markets: A Defensive Anchor or Driven by Innovation?
Via MarketMinute
Topics ETFs Economy Intellectual Property

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 104.63
When was Merck & Co last traded?
The last trade of Merck & Co was at 11/26/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 264.86B
How many shares of Merck & Co are outstanding?
Merck & Co has 265B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.